Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.
Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis (MCDA) model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.
The MCDA framework, the authors explained, allows methodological robustness with different phases and stages for implementation in the context of health technology assessment (HTA). The new model, they wrote, is a generic value-based model for HTA assessment that can be a decision-making tool for payers. The generic nature is in that it can be used for any type of health technology: medicines, medical devices, and other interventions in healthcare.
The paper explains that the basic model criteria include:
The researchers used a top-down, value-focused approach to incorporate value concerns of decision-makers while being adaptable to diverse decision problems. With respect to attribute definition and the choice of decision alternatives, they had a bottom-up approach for the sake of decision-specific assessment of performance of alternative treatments as needed.
The paper recommends a “value-alternative hybrid thinking” approach, which is, by design, a top-down approach, with decision alternatives being addressed as a bottom-up approach.
Their 5-stage iterative model-building approach used a top-down “value-focused thinking” approach that encompassed 5 steps:
Of the 2778 abstracts that were screened, a total of 255 articles were selected, and a 101 were finally used. In the European countries where these studies were conducted, the evaluation criteria were focused on:
This was only the model building phase, the authors stated in their discussion; model-assessment and model-appraisal phases need to follow. They recommended applying different types of MCDA modeling techniques for the actual value judgements and elicitation of preferences when multiple options are available.
The paper has been published in Social Science & Medicine.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More